Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | MAVORIC: mogamulizumab improves PFS for CTCL

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, discusses the findings of the Phase III randomized MAVORIC trial (NCT01728805) comparing the outcomes of patients with relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) who receive mogamulizumab versus vorinostat. Prof. Scarisbrick reports that the trial, which enrolled over 350 patients, demonstrated a significant progression-free survival (PFS) benefit amongst patients receiving mogamulizumab. Prof. Scarisbrick also highlights that there was an improvement in quality of life amongst patients receiving mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.